Suggested remit - To evaluate the benefits and costs of ravulizumab within its marketing authorisation for treating atypical haemolytic uraemic syndrome for national commissioning by NHS England.
 
Status In progress
Process STA 2018
ID number 1530

Provisional Schedule

Expected publication 23 June 2021

Project Team

Project lead Gavin Kenny

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Consultees

Companies sponsors Alexion Pharma UK (ravulizumab)
Others Department of Health and Social Care
  National Renal Complement Therapeutics Centre
  NHS England
Patient carer groups aHUS alliance Global Action
Professional groups British Association for Paediatric Nephrology
  British Transplantation Society
  Royal College of Physicians
  UK Renal Pharmacy Group

Commentators

Comparator companies Alexion Pharma UK (eculizumab) (confidentiality agreement not signed, not participating)
Evidence review group Centre for Reviews and Dissemination and Centre for Health Economics – York
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Welsh Government

Timeline

Key events during the development of the guidance:

Date Update
20 May 2021 - 04 June 2021 Final appraisal document
13 April 2021 Committee meeting
31 July 2020 Invitation to participate
06 July 2020 - 20 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 June 2020 In progress. In progress. This has now been rescheduled into the work programme and is due to be discussed at committee on 13 April 2021.
13 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
27 January 2020 (10:00) Scoping workshop (London)
02 December 2019 - 09 January 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance